FDA Rejects Over 889,000 Tobacco Applications for Noncompliance

Oct.17.2022
FDA Rejects Over 889,000 Tobacco Applications for Noncompliance
FDA rejects 889,000 tobacco product applications while accepting over 1,600, mostly for e-cigarettes and e-liquids. Warning letters sent to manufacturers and retailers.

The US Food and Drug Administration (FDA) has announced that it has issued more than 889,000 Refuse to Accept (RTA) letters as of October 7, to pre-market tobacco product applications (PMTAs) that do not meet acceptance criteria.


The organization also announced that the FDA has received over 1,600 applications, the majority of which are for electronic cigarettes or e-liquid products.


Although the review process is ongoing, the FDA remains vigilant in regulating the market and will continue to use our compliance and enforcement resources to curb the illegal marketing of non-tobacco nicotine products. To date, the FDA has issued more than 60 warning letters to manufacturers, including popular brands among young people such as Puff Bar," stated the FDA in a press release. "The warning letters include products that have submitted applications but have received negative actions from the agency.


The FDA has sent over 300 warning letters to retailers demanding that they cease selling synthetic nicotine e-cigarette products to minors, and has imposed civil fines on two retailers for selling e-cigarette products to minors.


So far, the FDA has not authorized any synthetic nicotine e-cigarette products. Therefore, all synthetic nicotine e-cigarette products on the market are being sold illegally and are at risk of FDA enforcement action," said the FDA. "Retailers or distributors selling or distributing unauthorized e-cigarettes are breaking the law and those engaging in such behavior will face FDA enforcement risks, such as seizures, injunctions, or civil fines.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of the content. The translation of this article is solely for industry exchange and research purposes.


Due to limitations in our translation abilities, the translated article may not fully represent the original text. Therefore, please refer to the original text for accurate information.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.


The ownership of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21
U.S. Chicago CBP Seizes $358,000 Worth of Illegal Vapes
U.S. Chicago CBP Seizes $358,000 Worth of Illegal Vapes
U.S. Customs and Border Protection (CBP) officers in Chicago seized 43,200 illicit vaping products valued at over $358,000 for violating the Federal Food, Drug, and Cosmetic Act. The shipment originated from China and was destined for Mississippi.
Nov.07 by 2FIRSTS.ai
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts observed on FOGER’s online retail site “FOGER VAPES” that the platform indicates restocking delays due to customs and tariff factors. Several items show limited availability or “sold out” status, with a restock alert feature offered. A previous article on the site also referenced potential tariff changes that may affect pricing.
Nov.05
2025 China Shenzhen Top 500 Enterprises List: 13 E-cigarette Companies Include
2025 China Shenzhen Top 500 Enterprises List: 13 E-cigarette Companies Include
Shenzhen e-commerce companies dominate 2025 Top 500 list, including 13 e-cigarette businesses. Shenzhen FirstUnion Tech climbs 57 spots.
Oct.30 by 2FIRSTS.ai
2Firsts Observations | Two Months After Launch, BAT’s VELO Shift Draws Attention for Non-Traditional Design as Some Users Call for Higher Nicotine Strength
2Firsts Observations | Two Months After Launch, BAT’s VELO Shift Draws Attention for Non-Traditional Design as Some Users Call for Higher Nicotine Strength
British American Tobacco (BAT) introduced the VELO Shift nicotine pouch in September 2025, featuring a hexagonal outer can and an oval-triangle pouch shape that departs from traditional designs. Two months after launch, the product is available in the U.K., U.S. and Sweden. Social-media feedback indicates the design has been well received, while some users are calling for higher nicotine strength.
Nov.06 by 2FIRSTS.ai
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.
Oct.21